Lien vers Pubmed [PMID] – 32360825
Clin. Gastroenterol. Hepatol. 2020 Apr;
Scale-up of tests and treatments is needed to eliminate hepatitis B virus (HBV) infection from resource-limited countries. However, access to nucleic acid tests that quantify HBV DNA, to determine treatment eligibility, is severely limited. We performed a systematic review and meta-analysis to assess the performance of the hepatitis B core-related antigen (HBcrAg) immunoassay, a low-cost (less than $15/assay) alternative to the nucleic acid test, to identify highly viremic patients, infected with any HBV genotype.
https://www.ncbi.nlm.nih.gov/pubmed/32360825